Biotron Limited
A.B.N. 60 086 399 144

RESULTS OF ANNUAL GENERAL MEETING

25 November 2026, **Biotron Limited** (ASX: **BIT**) held its Annual General Meeting of Shareholders at 11:00am today at Level 38, Tower 3, International Towers Sydney, 300 Barangaroo Ave, Sydney, NSW 2000.

All resolutions were determined and passed by a poll.

The outcome of each resolution put to shareholders at the Annual General Meeting is set out in the Annexure, which accompanies this release.

This announcement has been authorised for release by the CEO and Executive Director of Biotron Limited, Mr Glenn Gilbert.

FOR FURTHER INFORMATION

Marcelo Mora
Company Secretary
Biotron Limited
T: +61 2 9300 3344
E: mmora@miscorp.com.au
W: www.biotron.com.au

pjn13067

About Biotron Limited

Biotron Limited (ASX: BIT) is an Australian biotechnology company focused on developing and commercialising novel therapeutics across anaesthesia, neuroscience, and antiviral medicine. Its lead asset, SedRx, is a next-generation alfaxalone-based general anaesthetic supported by existing human clinical data and being advanced through regulatory planning for pivotal development, alongside evaluation of additional neuroscientific indications. Biotron also continues to develop BIT-HBV001, a novel antiviral candidate targeting Hepatitis B and Hepatitis Delta viruses, while pursuing partnering and commercialisation opportunities across its portfolio.

Results of Meeting

Biotron Limited

Annual General Meeting

Wednesday, 25 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of the Remuneration Report	P	642,561,154 92.19%	52,254,394 7.50%	6,325,152	2,207,882 0.32%	645,183,258 92.51%	52,254,394 7.49%	6,325,152	-
2 Re-election of Mr Michael J. Medway as a Director	P	863,059,358 89.23%	101,916,385 10.54%	9,455,154	2,207,882 0.23%	865,681,959 89.47%	101,916,385 10.53%	9,455,154	Carried
3 Re-election of Dr Paul A. Kasian as a Director	P	921,856,974 94.42%	52,223,914 5.35%	350,009	2,207,882 0.23%	924,479,575 94.65%	52,223,914 5.35%	350,009	Carried
4 Re-election of Dr Graeme D. Wald as a Director	P	499,650,664 51.66%	465,325,079 48.11%	9,455,154	2,207,882 0.23%	502,273,265 51.91%	465,325,079 48.09%	9,455,154	Carried
5 Re-Election of Dr Michael J. Thurn as a Director	P	932,804,829 95.55%	32,170,914 3.30%	350,009	11,313,027 1.16%	944,532,575 96.71%	32,170,914 3.29%	350,009	Carried
6 Approval of 10% Placement Facility	P	901,737,108 94.71%	39,101,079 4.11%	24,487,565	11,313,027 1.19%	913,464,854 95.90%	39,101,079 4.10%	24,487,565	Carried